Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | CLK1 | P49759 | 1/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
| ▸ | PABPC1 | P11940 | 3/20 | 0.60 |
| ▸ | EIF4H | Q15056 | 3/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29728211 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAHTTSMN1; SMN2MEN1 | |
| SCHEMBL28270221 | 0.89 | HTT (0.81) | ALDH1A1LMNAHTTSMN1; SMN2MEN1 | |
| SCHEMBL9186736 | 0.88 | ALDH1A1 (0.79) | ALDH1A1LMNAHTTSMN1; SMN2MEN1 | |
| SCHEMBL6030648 | 0.85 | ALDH1A1 (0.74) | ALDH1A1LMNAHTTSMN1; SMN2MEN1 | |
| SCHEMBL21296583 | 0.85 | ALDH1A1 (0.74) | ALDH1A1LMNAHTTSMN1; SMN2MEN1 | |
| SCHEMBL6030652 | 0.85 | ALDH1A1 (0.74) | ALDH1A1LMNAHTTSMN1; SMN2MEN1 | |
| SCHEMBL8402846 | 0.85 | ALDH1A1 (0.74) | ALDH1A1LMNAHTTSMN1; SMN2MEN1 | |
| SCHEMBL27617527 | 0.85 | ALDH1A1 (0.74) | ALDH1A1LMNAHTTSMN1; SMN2MEN1 | |
| SCHEMBL2639029 | 0.82 | ALDH1A1 (0.70) | ALDH1A1LMNAHTTSMN1; SMN2MEN1 | |
| SCHEMBL4861658 | 0.82 | ALDH1A1 (0.70) | ALDH1A1LMNAHTTSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240131032-A1 | AN ACTIVITY-GUIDED MAP OF ELECTROPHILE-CYSTEINE INTERACTIONS IN PRIMARY HUMAN IMMUNE CELLS | THE SCRIPPS RESEARCH INSTITUTE | 2024-04-25 | — | — | US | disclosed |
| US-20240123078-A1 | COMPOUNDS AND METHODS FOR MODULATING IMMUNE-RELATED PROTEINS | VIVIDION THERAPEUTICS, INC. | 2024-04-18 | — | — | US | disclosed |
| CN-116406231-A | Molecules having certain pesticidal utility, and intermediates, compositions and methods related thereto | 科迪华农业科技有限责任公司 | 2023-07-07 | — | — | CN | disclosed |
| US-20220298213-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | VIVIDION THERAPEUTICS, INC. | 2022-09-22 | — | — | US | disclosed |
| EP-4045050-A1 | AN ACTIVITY-GUIDED MAP OF ELECTROPHILE-CYSTEINE INTERACTIONS IN PRIMARY HUMAN IMMUNE CELLS | The Scripps Research Institute (US) | 2022-08-24 | — | — | EP | disclosed |
| CN-109265451-B | Butyrylcholinesterase selective inhibitor and preparation method and application thereof | 中国药科大学 | 2022-07-15 | — | — | CN | disclosed |
| WO-2022132609-A1 | MOLECULES HAVING CERTAIN PESTICIDAL UTILITIES, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES RELATED THERETO | CORTEVA AGRISCIENCE LLC (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2021076755-A1 | AN ACTIVITY-GUIDE MAP OF ELECTROPHILE-CYSTEINE INTERACTIONS IN PRIMARY HUMAN IMMUNE CELLS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-04-22 | — | — | WO | disclosed |
| WO-2021076755-A1 | AN ACTIVITY-GUIDE MAP OF ELECTROPHILE-CYSTEINE INTERACTIONS IN PRIMARY HUMAN IMMUNE CELLS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-04-22 | — | — | WO | disclosed |
| US-20210002337-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | THE SCRIPPS RESEARCH INSTITUTE | 2021-01-07 | — | — | US | disclosed |
| US-20040152890-A1 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. | 2004-08-05 | — | — | US | disclosed |
| WO-2004052887-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2004-06-24 | — | — | WO | disclosed |
| US-20030212011-A1 | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG (CH) | 2003-11-13 | — | — | US | disclosed |
| WO-2003072588-A1 | MACROLIDES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2003-09-04 | — | — | WO | disclosed |
| EP-1242427-B1 | NOVEL PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2003-08-13 | — | — | EP | disclosed |
| CN-1434827-A | Novel piperidine and piperazine derivatives | ASTRAZENECA AB (SE) | 2003-08-06 | — | — | CN | disclosed |
| US-20030013721-A1 | Novel piperidine and piperazine derivatives | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | US | disclosed |
| EP-1242427-A1 | NOVEL PIPERIDINE AND PIPERAZINE DERIVATIVES | AstraZeneca AB (SE) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001046200-A1 | NOVEL PIPERIDINE AND PIPERAZINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | disclosed |
| EP-0443862-A1 | Triamine derivatives and their acid-addition salts | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1991-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298213-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | CRBN, CDR2, DCUN1D4 | ALDH1A1 2798/4885LMNA 1798/4885HTT 3236/4885 |
| US-20240123078-A1 | COMPOUNDS AND METHODS FOR MODULATING IMMUNE-RELATED PROTEINS | CD4, ICOS, NFATC1 | ALDH1A1 4719/4885LMNA 4512/4885HTT 3649/4885 |
| US-20030212011-A1 | Macrolides with antibacterial activity | MRPL21, RPS21, MRPS18A | ALDH1A1 3345/4885LMNA 2498/4885HTT 3924/4885 |
| US-20240131032-A1 | AN ACTIVITY-GUIDED MAP OF ELECTROPHILE-CYSTEINE INTERACTIONS IN PRIMARY HUMAN IMMUNE CELLS | GSTK1, GSTA2, GSTA1 | ALDH1A1 1423/4885LMNA 4748/4885HTT 4016/4885 |
| US-20030013721-A1 | Novel piperidine and piperazine derivatives | IL5, VIP, EP300 | ALDH1A1 68/4885LMNA 3352/4885HTT 2520/4885 |
| US-20210002337-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | CRBN, CDR2, DCUN1D4 | ALDH1A1 2798/4885LMNA 1798/4885HTT 3236/4885 |
| US-20040152890-A1 | Substituted heterocyclic compounds | KCNH1, SDHA, COQ8A | ALDH1A1 245/4885LMNA 2835/4885HTT 2557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.